Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer, Cholangiocarcinoma
Conditions
Brief summary
DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder.
Detailed description
In Part A, escalating doses of DKN-01 will be administered to different cohorts of patients to evaluate safety and dose limiting toxicities (DLTs) and to establish the maximum tolerated dose of DKN-01 when administered in combination with gemcitabine and cisplatin. Part B is an expansion cohort in which patients are treated at the MTD of DKN-01 (or highest dose tested if the MTD is not defined) to further characterize safety, tolerability, pharmacokinetics and efficacy within the defined patient population.
Interventions
DRUGDKN-01
Administration by intravenous (IV) infusion.
DRUGgemcitabine
Administered by IV infusion.
DRUGcisplatin
Administered by IV infusion
Sponsors
Leap Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient has carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder. 2. Patient must have sufficient tumor tissue available for submission. 3. For patients who have received prior cryotherapy, radiofrequency ablation, radioembolization, ethanol injection, transarterial chemoembolization (TACE) or photodynamic therapy, at least 28 days must have elapsed since that therapy, and lesions that have not been treated with local therapy must be present and measurable. 4. Patients may have received prior adjuvant chemotherapy with gemcitabine with or without cisplatin, as long as 6 months have elapsed since last treatment. 5. Patients must have one or more tumors measurable on radiographic imaging as defined by RECIST. 6. ECOG PS of 0 or 1. Patients with an ECOG PS of 2 may be entered upon review and approval of the medical monitor. 7. Estimated life expectancy of at least 3 months. 8. Disease-free of active second/secondary or prior malignancies for ≥ 2 years with the exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast. 9. Adequate hematological, renal, hepatic and coagulation laboratory test results. 10. Women of child bearing potential and men must agree to use adequate contraception during the study and for 6 months after their last dose of study drug. 11. Available for the duration of the study and are willing to follow study-specific procedures. 12. Provide written informed consent
Exclusion criteria
1. New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, or unstable arrhythmia. 2. Have Fridericia-corrected QT interval (QTcF) \> 470 msec (female) or \> 450 (male), or history of congenital long QT syndrome. 3. Active, uncontrolled bacterial, viral, or fungal infections. 4. Known to be human immunodeficiency virus (HIV) positive or has untreated, active hepatitis B. 5. History of major organ transplant. 6. History of an autologous/allogenic bone marrow transplant. 7. Serious nonmalignant disease. 8. Pregnant or nursing. 9. History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on MRI scan that are symptomatic and clinically significant. 10. Symptomatic central nervous system (CNS) malignancy or metastasis. 11. Clinically significant peripheral neuropathy 12. Known osteoblastic bony metastasis. 13. Treatment with surgery or chemotherapy within 21 days prior to study entry or radiation within 14 days of study entry. 14. Previously treated with an anti-Dkk-1 therapy. 15. Other exclusions apply
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose and dose-limiting toxicities as determined in Part A. | End of Cycle 1 (Day 21) | Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 4.03). |
| Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events. | Parts A and B: at a minimum Days 1, 8, 15 of each treatment cycle. | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics - AUC | Cycle 1 - Days 1 and 8, Cycle 2 - Day 1 | Plasma levels will be measured during the treatment period. |
| Pharmacokinetics - Cmax | Cycle 1 - Days 1 and 8, Cycle 2 - Day 1 | Plasma levels will be measured during the treatment period. |
| Pharmacokinetics - Tmax | Cycle 1 - Days 1 and 8, Cycle 2 - Day 1 | Plasma levels will be measured during the treatment period. |
| Efficacy - Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1) | At baseline, prior to the start of Cycle 3, and every 2 cycles thereafter until disease progression or death | Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1). |
Countries
United States
Outcome results
None listed